Is ANI ( ANIP ) a Solid Growth Stock? 3 Reasons to Think "Yes"
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
Is Amarin ( AMRN ) Stock Outpacing Its Medical Peers This Year?
Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
ANI Pharmaceuticals, Inc. ( ANIP ) Hits Fresh High: Is There Still Room to Run?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cg Oncology ( CGON ) Q2 Loss Widens 93%
Cg Oncology ( NASDAQ:CGON ) , a clinical-stage biotechnology company focused on developing therapies for bladder cancer, reported its second quarter fiscal 2025 earnings on August 8, 2025. The company disclosed a net loss that was more than double that of the same quarter in 2024.
ANI Pharmaceuticals ( ANIP ) Q2 Earnings and Revenues Surpass Estimates
ANI (ANIP) delivered earnings and revenue surprises of +30.43% and +12.22%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting -
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( Nasdaq: ANIP ) ( ANI or the Company ) today announced financial results and business highlights for the second quarter ended June 30, 2025.
Sutro Biopharma, Inc. ( STRO ) Reports Q2 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) delivered earnings and revenue surprises of +64.10% and +293.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( NASDAQ: ANIP ) today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ANIP today announced that the Company will release its second quarter 2025 financial results on Friday, August 8, 2025, prior to the market open.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Kymera Therapeutics, Inc. ( KYMR ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ANI Pharmaceuticals ( ANIP ) Earnings Expected to Grow: What to Know Ahead of Q2 Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kiniksa Pharmaceuticals International, plc ( KNSA ) Tops Q2 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +27.78% and +7.92%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema ( DME ) - ANI Pharmaceuticals ( NASDAQ:ANIP )
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm Study Enrolled Treatment-Naïve, or Almost Naïve, Patients with DME Results presented by Michael A.
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema ( DME )
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc. ( NASDAQ: AQST ) ( "Aquestive" or the "Company" ) , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced ...
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - Aquestive Therapeutics ( NASDAQ:AQST )
WARREN, N.J., July 22, 2025 ( GLOBE NEWSWIRE ) -- Aquestive Therapeutics, Inc.
Will ANI ( ANIP ) Beat Estimates Again in Its Next Earnings Report?
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, ...
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., July 02, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( "ANI" or the "Company" ) ANIP today announced that Nikhil Lalwani, President and Chief Executive Officer, will host 1x1 meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on Tuesday, July 8, ...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology ( EULAR ) 2025 Congress The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster ...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced new preclinical data on the use of Purified Cortrophin Gel ( repository corticotropin injection USP ) ( Cortrophin Gel ) in a mouse model of murine collagen-induced ...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
PRINCETON, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows: ...
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., May 27, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global Healthcare Conference in New York City as follows:
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Agilon Health ( NYSE:AGL ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares
Purified Cortrophin Gel is the only ACTH therapy approved by the FDA for the treatment of acute gout flares ...
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ
PRINCETON, N.J., May 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ( Nasdaq: ANIP ) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C.
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - ANI Pharmaceuticals ( NASDAQ:ANIP )
PRINCETON, N.J., May 12, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( ANI or the Company ) ANIP today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at ...
ANI ( ANIP ) is an Incredible Growth Stock: 3 Reasons Why
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact - ANI Pharmaceuticals ( NASDAQ:ANIP )
Q1 adjusted EPS rose to $1.70 vs. $1.21 last year, beating the $1.38 consensus. Total revenue up 43.4% to $197.12 million; rare disease sales jumped 86.7% to $69 million. Don't miss this list of 3 high-yield stocks-including one delivering over 10%-built for income in today's chaotic market.
Is ANI Pharmaceuticals ( ANIP ) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading ...
ANI Pharmaceuticals ( ANIP ) Tops Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of 24.09% and 9.85%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., May 09, 2025 ( GLOBE NEWSWIRE ) -- ANI Pharmaceuticals, Inc. ( Nasdaq: ANIP ) ( ANI or the Company ) today announced financial results and business highlights for the first quarter ended March 31, 2025.
Pacira ( PCRX ) Q1 Earnings Surpass Estimates
Pacira (PCRX) delivered earnings and revenue surprises of 8.77% and 3.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
WAT's first-quarter 2025 results reflect strong growth in the instruments and chemical segments, coupled with strong momentum in the industrial and pharma sectors.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Halozyme reports better-than-expected first-quarter 2025 results. The company increases revenue guidance for 2025. Shares rise.
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards?
ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products.
DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.
ANI Pharmaceuticals, Inc. ( ANIP ) Hit a 52 Week High, Can the Run Continue?
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
